Immunoassay Market

Key Players: Companies such as Abbott Laboratories (US), Roche Diagnostics (CH), Siemens Healthineers (DE), Thermo Fisher Scientific (US), Ortho Clinical Diagnostics (US), Bio-Rad Laboratories (US), Danaher Corporation (US), PerkinElmer (US), Fujirebio (JP) are some of the major participants in the global market.

Immunoassay Market

Immunoassay Market Research Report: Size, Share, Trend Analysis By Types (Enzyme-Linked Immunosorbent Assay, Radioimmunoassay, Fluorescent Immunoassay, Chemiluminescent Immunoassay, Western Blot), By Technology (Automated Immunoassay, Point of Care Immunoassay, Lateral Flow Assay), By Applications (Clinical Diagnostics, Drug Development, Environmental Testing, Food Safety Testing), By End Use (Hospitals, Diagnostic Laboratories, Pharmaceutical Companies, Academic Research Institutions) and By Region (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth Outlook & Industry Forecast 2025 To 2035
ID: MRFR/HC/4385-HCR
200 Pages
Vikita Thakur, Rahul Gotadki
Last Updated: April 15, 2026
Request Free Sample

Immunoassay Market Summary

According to MRFR analysis, the Immunoassay Market Size was valued at USD 25.25 Billion in 2024. The market is projected to grow from USD 26.22 Billion in 2025 to USD 38.3 Billion by 2035, registering a CAGR of 3.8% during the forecast period (2025–2035). North America led the market with over 41.98% share, generating around USD 10.6 billion in revenue.
 
The Immunoassay Market is expanding due to increasing demand for rapid and accurate diagnostic testing in clinical and research settings. Key trends include advancements in ELISA and lateral flow assay technologies, growing adoption of automated immunoassay platforms, and rising applications in disease detection, drug development, and personalized medicine globally.

Key Market Trends & Highlights

The Immunoassay Market is experiencing robust growth driven by technological advancements and increasing demand for personalized healthcare solutions.

  • North America remains the largest market for immunoassays, driven by advanced healthcare infrastructure and high adoption rates.
  • The Asia-Pacific region is emerging as the fastest-growing market, fueled by increasing investments in healthcare and rising awareness of preventive measures.
  • Chemiluminescent immunoassays dominate the market, while enzyme-linked immunosorbent assays are witnessing rapid growth due to their versatility and cost-effectiveness.
  • Key market drivers include the increasing prevalence of chronic diseases and advancements in immunoassay technologies, which are enhancing diagnostic capabilities.

Market Size & Forecast

2024 Market Size 25.25 (USD Billion)
2035 Market Size 38.3 (USD Billion)
CAGR (2025 - 2035) 3.86%

Major Players

Companies such as Abbott Laboratories (US), Roche Diagnostics (CH), Siemens Healthineers (DE), Thermo Fisher Scientific (US), Ortho Clinical Diagnostics (US), Bio-Rad Laboratories (US), Danaher Corporation (US), PerkinElmer (US), Fujirebio (JP) are some of the major participants in the global market.

Our Impact
Enabled $4.3B Revenue Impact for Fortune 500 and Leading Multinationals
Partnering with 2000+ Global Organizations Each Year
30K+ Citations by Top-Tier Firms in the Industry

Immunoassay Market Trends

The Immunoassay Market is currently experiencing a dynamic evolution, driven by advancements in technology and increasing demand for rapid diagnostic solutions. The integration of automation and artificial intelligence into immunoassay systems appears to enhance accuracy and efficiency, thereby attracting a broader range of applications in clinical laboratories and point-of-care settings.

Furthermore, the growing prevalence of chronic diseases and the need for timely detection are likely to propel the market forward, as healthcare providers seek reliable testing methods to improve patient outcomes. In addition, the trend towards personalized medicine is influencing the market, as tailored therapies require precise monitoring of biomarkers. This shift necessitates the development of innovative assays that can provide specific and sensitive results.

Regulatory bodies are also adapting to these changes, potentially streamlining approval processes for new immunoassay technologies. Overall, the market seems poised for substantial growth, with ongoing research and development efforts likely to yield novel solutions that meet the evolving needs of healthcare professionals and patients alike.

Technological Advancements

Recent innovations in immunoassay technology, including automation and AI integration, are enhancing the precision and speed of diagnostic tests. These advancements facilitate the development of more sophisticated assays, which may lead to improved patient care.

The Immunoassay Market is witnessing rapid technological advancements with the integration of automation and artificial intelligence in diagnostic platforms. These innovations improve test accuracy and processing efficiency in clinical laboratories. According to the World Health Organization, non-communicable diseases account for nearly 74% of global deaths, increasing the demand for reliable biomarker-based diagnostic tests such as immunoassays.

Rising Demand for Point-of-Care Testing

The increasing preference for point-of-care testing is reshaping the Immunoassay Market. This trend reflects a shift towards decentralized healthcare, where rapid results are essential for timely decision-making in clinical settings.

Point-of-care testing is gaining significant traction as healthcare systems focus on faster diagnostics and decentralized care. According to the Centers for Disease Control and Prevention, over 6 in 10 adults in the United States live with at least one chronic disease, driving the need for rapid testing solutions that can support timely clinical decision-making.

Focus on Personalized Medicine

The growing emphasis on personalized medicine is driving the need for specific and sensitive immunoassays. As healthcare moves towards tailored therapies, the demand for assays that can accurately monitor individual biomarkers is likely to rise.

The growing emphasis on personalized medicine is increasing the demand for highly sensitive immunoassays capable of monitoring specific biomarkers. The National Institutes of Health notes that precision medicine initiatives now involve more than one million participants in genomic and biomarker research programs, supporting the development of advanced diagnostic assays tailored to individual patient profiles.

Immunoassay Market Drivers

Advancements in Immunoassay Technologies

Technological innovations in immunoassay methodologies are significantly influencing the Immunoassay Market. The introduction of novel platforms, such as microfluidics and multiplex assays, enhances the efficiency and accuracy of diagnostic testing. These advancements allow for the simultaneous detection of multiple analytes, thereby streamlining the testing process and reducing turnaround times.
 
Furthermore, the integration of automation and artificial intelligence in immunoassay systems is expected to improve operational efficiency in laboratories. As a result, the market is projected to expand, with an estimated growth rate of over 8% annually in the coming years. This technological evolution not only meets the increasing demand for rapid diagnostics but also positions the Immunoassay Market at the forefront of modern healthcare solutions.

Increasing Prevalence of Chronic Diseases

The rising incidence of chronic diseases such as diabetes, cardiovascular disorders, and infectious diseases is a primary driver for the Immunoassay Market. As healthcare systems strive to manage these conditions effectively, the demand for accurate and rapid diagnostic tools has surged. According to recent data, chronic diseases account for approximately 70% of all deaths worldwide, necessitating the need for reliable testing methods.
 
Immunoassays, known for their sensitivity and specificity, are increasingly utilized in clinical laboratories and point-of-care settings. This trend is expected to continue, as healthcare providers seek to enhance patient outcomes through timely diagnosis and monitoring. Consequently, the market is likely to experience substantial growth as it adapts to the evolving healthcare landscape.

Growing Awareness of Preventive Healthcare

The increasing emphasis on preventive healthcare is driving the Immunoassay Market. As individuals become more health-conscious, there is a heightened demand for early detection and monitoring of diseases. Immunoassays play a crucial role in preventive healthcare by enabling timely diagnosis and facilitating proactive management of health conditions.
 
Market Research Future indicates that preventive healthcare spending is projected to rise significantly, reflecting a shift in focus from reactive to proactive health management. This trend is likely to bolster the demand for immunoassay tests, as healthcare providers and patients alike recognize the value of early intervention. Consequently, the market is poised for growth as it aligns with the broader movement towards preventive health strategies.

Rising Demand for Home Healthcare Solutions

The growing preference for home healthcare solutions is reshaping the Immunoassay Market. Patients increasingly seek convenient and accessible testing options that can be performed in the comfort of their homes. This trend is driven by a desire for personalized care and the need to reduce hospital visits. The market tests that are designed for home use, such as rapid tests for pregnancy and infectious diseases, are gaining traction. 
 
Market data indicates that the home healthcare segment is expected to witness a compound annual growth rate of approximately 10% over the next few years. This shift towards home-based testing not only enhances patient engagement but also drives innovation within the Immunoassay Market, as manufacturers develop user-friendly and reliable testing kits.

Regulatory Support for Diagnostic Innovations

Regulatory bodies are increasingly supporting innovations in diagnostic testing, which is positively impacting the Immunoassay Market. Streamlined approval processes for new immunoassay technologies facilitate quicker market entry for novel products. This regulatory environment encourages research and development, leading to the introduction of advanced diagnostic solutions.
 
For instance, recent initiatives aimed at expediting the approval of point-of-care tests have opened new avenues for growth within the market. As a result, the market is likely to benefit from enhanced product offerings and increased competition, ultimately leading to improved patient care and outcomes. The proactive stance of regulatory agencies is expected to sustain the momentum of innovation in the immunoassay sector.

Market Segment Insights

By Type: Chemiluminescent Immunoassay (Largest) vs. Enzyme-Linked Immunosorbent Assay (Fastest-Growing)

The Immunoassay Market is characterized by diverse methodologies, with the Chemiluminescent Immunoassay (CLIA) segment leading in market share due to its broad application in immunoassay diagnostics and increased sensitivity. Enzyme-Linked Immunosorbent Assay (ELISA) is gaining momentum as a vital tool in research and clinical settings, showcased by its substantial growth rate. Collectively, these methods cater to various therapeutic areas, including infectious diseases, hormone levels, and cancer detection, solidifying their integral roles in the healthcare realm. As the demand for efficient and precise diagnostic tools escalates, innovative technologies in Chemiluminescent Immunoassays continue to evolve, driving their dominance. Conversely, the emerging ELISA techniques are witnessing rapid advancements due to their cost-effectiveness and stellar reliability, enabling their penetration into new markets. Market players are focusing on enhancing assay performance and developing kits that cater to a broader range of diseases, prompting companies to capitalize on emerging trends and advancements to meet evolving customer needs.

Chemiluminescent Immunoassay (Dominant) vs. Enzyme-Linked Immunosorbent Assay (Emerging)

Chemiluminescent Immunoassays (CLIA) and Enzyme-Linked Immunosorbent Assays (ELISA) represent two significant methods in the immunoassay domain. CLIA is known for its rapid results and high sensitivity, making it the preferred choice in clinical laboratories for hormone and infectious disease testing. Its automated nature allows for high-throughput testing, aligning with the industry's shift towards efficiency. On the other hand, ELISA, while traditionally viewed as a standard, is evolving with innovative modifications that enhance its sensitivity and specificity. As a classic method, ELISA remains widely utilized across various applications, but it is increasingly being augmented to compete with more modern techniques. The distinct characteristics of each method underline their respective market positions, with CLIA currently dominating, while ELISA is set for significant growth.

By Technology: Automated Immunoassay (Largest) vs. Point of Care Immunoassay (Fastest-Growing)

The Immunoassay Market is segmented primarily into Automated Immunoassay, Point of Care Immunoassay, and Lateral Flow Assay. Among these, the Automated Immunoassay segment holds the largest share due to its widespread adoption in laboratories and diagnostic settings. With its high throughput and efficiency, Automated Immunoassays provide consistent results that are crucial for laboratory immunoassay diagnostics. Meanwhile, the Point of Care Immunoassay segment is rapidly gaining traction, driven by rising demand for rapid testing solutions in various healthcare settings, making it the fastest-growing segment in this market.

Technology: Automated Immunoassay (Dominant) vs. Point of Care Immunoassay (Emerging)

The Automated Immunoassay segment is the dominant player in the market, characterized by high precision, reproducibility, and the ability to handle a large volume of tests simultaneously. This segment is primarily utilized in clinical laboratories where efficiency and accuracy are paramount. On the other hand, the Point of Care Immunoassay segment is emerging as a significant innovation, providing quick and reliable results directly at the patient's location. This shift towards immediate testing is being fueled by technological advancements, increased patient engagement, and the rising prevalence of chronic diseases that require consistent monitoring. The Lateral Flow Assay, while established, is positioned as a crucial tool in specific applications such as home testing kits and infectious disease diagnostics.

By Application: Clinical Diagnostics (Largest) vs. Drug Development (Fastest-Growing)

The market is segmented into Clinical Diagnostics, Drug Development, Environmental Testing, and Food Safety Testing. Clinical Diagnostics holds the largest Immunoassay Market share, driven by the rising prevalence of chronic diseases. Drug Development is notable for its rapid growth as pharmaceutical companies increasingly rely on immunoassays for the development of new therapeutics. Environmental Testing and Food Safety Testing are also significant, but their shares are smaller in comparison, reflecting a more niche application of immunoassays primarily focused on regulatory compliance and safety assurance. Growth trends within this segment are favorable, with Clinical Diagnostics continuing to be propelled by technological advancements and the increasing demand for point-of-care testing. Drug Development is witnessing the fastest growth due to heightened investment in pharmaceuticals and biotechnologies seeking efficiency in drug discovery processes. Overall, the application of immunoassays in these sectors is expanding, indicating a robust overall growth trajectory for the market during the coming years.

Clinical Diagnostics (Dominant) vs. Drug Development (Emerging)

Clinical Diagnostics represents the dominant application within the Immunoassay Market, encompassing tests that are routinely used for the diagnosis of diseases such as diabetes, cardiac markers, and infectious diseases. Its strong market position stems from the widespread adoption of immunoassay techniques in laboratories and clinics, coupled with the growing emphasis on early disease detection. On the other hand, Drug Development is emerging as a rapidly growing area, driven by innovations in drug discovery and the increasing need for efficient testing methodologies. The integration of immunoassays in clinical trials is vital, as it enhances the reliability and speed of therapeutic assessments. Together, these segments illustrate a dynamic and evolving landscape in immunoassay applications.

By End Use: Hospitals (Largest) vs. Diagnostic Laboratories (Fastest-Growing)

By end use, with hospitals being the largest contributor. This segment holds a significant Immunoassay Market share due to the high volume of diagnostic tests performed in healthcare settings. Hospitals leverage immunoassay tests for a variety of clinical applications, including disease diagnosis and monitoring, which sustains their leading position in this market. In contrast, diagnostic laboratories are emerging as a rapidly growing segment, primarily driven by the increasing demand for specialized diagnostic services and innovations in testing methods.

Hospitals (Dominant) vs. Diagnostic Laboratories (Emerging)

Hospitals are the dominant end-use segment in the market, primarily due to the extensive volume of tests carried out in clinical environments. They benefit from established workflows, integrated systems, and access to patient samples, which facilitates rapid diagnosis and treatment decisions. On the other hand, diagnostic laboratories are considered an emerging segment, spurred by advancements in technology and an increasing emphasis on personalized medicine. These labs are optimizing their resources and workflows to cater to growing test volumes, which enhances their market presence. Their adaptability to incorporate innovative testing for immunoassay platforms positions them as key players, able to respond swiftly to evolving market needs and regulatory demands.

Get more detailed insights about Immunoassay Market
Request Free Sample

Regional Insights

North America leads in the Immunoassay Market Size, accounting for over 41.98% of the global revenue in 2024, showcasing its majority holding in the therapeutic drug monitoring market due to advanced healthcare infrastructure and high adoption of immunoassay techniques. Europe follows closely, with a valuation of 8.2 USD Billion in 2024, projected to rise to 12.5 USD Billion, driven by an increasing focus on healthcare research and innovation.

Europe Immunoassay Market size was valued at USD 8.2 Billion in 2024, making it the second-largest regional market with a 32.48% share, regional governments prioritize improving healthcare access and diagnostics. South America, valued at 1.7 USD Billion, is expected to grow to 2.4 USD Billion, highlighting emerging trends in healthcare investment.

The Middle East and Africa (MEA) region, though the smallest at 0.62 USD Billion in 2024, signifies opportunities for expansion due to increasing awareness of immunodiagnostic applications.This regional breakdown illustrates varied growth trajectories, reflecting distinct healthcare dynamics and investment opportunities across the Global Market.

Immunoassay Market Regional Image

Key Players and Competitive Insights

The Global Immunoassay Market is characterized by its dynamic and competitive landscape, driven by technological advancements, increasing demand for accurate diagnostics, and a rising prevalence of chronic diseases. The competitive insights reflect a diverse range of players engaged in developing innovative immunoassay techniques and products. As the market continues to evolve, key competitors are vying for market share by enhancing their product portfolios and expanding their geographical reach.
 
Companies are increasingly focusing on strategic approaches such as partnerships, collaborations, and mergers to leverage each other's strengths, thereby gaining a competitive edge. The ongoing trend towards automation and the integration of artificial intelligence in diagnostic tools are also influencing market dynamics, contributing to the overall growth and competitive positioning of organizations within the sector.Abbott Laboratories has established a significant presence in the Global Immunoassay Market, leveraging its extensive experience and robust research and development capabilities.
 
The company is renowned for its innovative diagnostic solutions, offering a wide array of immunoassay products that cater to various therapeutic areas. Abbott's commitment to advancing healthcare solutions is a key strength, as it consistently invests in new technologies and methodologies to improve diagnostic accuracy and efficiency. The company benefits from a strong global distribution network, enabling it to reach a diverse customer base and respond adeptly to regional market needs.
 
Its established brand reputation and robust portfolio of immunoassay systems solidify Abbott Laboratories' position as a leading player in this competitive market. Hologic is another influential player in the Global Immunoassay Market, recognized for its specialized focus on women's health and infectious diseases. The company offers a variety of innovative immunoassay products, including assays for the detection of sexually transmitted infections and other health conditions.
 
Hologic's strengths lie in its commitment to innovation, with a strong emphasis on research and development that drives product advancement and clinical applications. The company has made significant strides in expanding its market presence through strategic mergers and acquisitions, allowing it to integrate complementary technologies and enhance its service offerings. This proactive approach not only broadens Hologic's product range but also strengthens its competitive position on a global scale, making it a formidable force within the immunoassay sector.

Key Companies in the Immunoassay Market include

Industry Developments

The Global Immunoassay Market has recently witnessed significant developments, particularly with key players such as Abbott Laboratories, Hologic, and Thermo Fisher Scientific pushing forward innovations in diagnostic tools. Notably, in July 2023, Abbott Laboratories announced the launch of a new immunoassay test designed for early detection of diseases, enhancing its product portfolio. Additionally, Quest Diagnostics is expanding its capabilities with new partnerships aimed at integrating advanced technologies in immunoassays.

Therapeutic drug monitoring market trends suggest rapid growth as the valuation of companies like Merck KGaA and Roche Diagnostics increases, driven by the rising demand for faster and more accurate diagnostic tests amid global health challenges. Furthermore, in a strategic move, Danaher Corporation acquired a smaller biotech firm in August 2023 to bolster its immunoassay capabilities. The immuno oncology assays market has seen strong performance overall, attributed to advancements in Research and Development and increasing end-user adoption across clinical laboratories and hospitals.

In the last two years, significant advancements have been noted, such as the introduction of point-of-care immunoassay devices in May 2022, which have revolutionized diagnostic procedures. Major socioeconomic factors and ongoing healthcare needs continue to influence trends within the Global Immunoassay Market.

Future Outlook

Immunoassay Market Future Outlook

The Immunoassay Market size is projected to reach USD 38.3 Billion by 2035, growing at a CAGR of 3.8%, driven by technological advancements, increasing demand for rapid immunoassay diagnostics, and expanding applications in personalized medicine.

New opportunities lie in:

  • Development of point-of-care testing devices for remote diagnostics. Integration of AI in immunoassay data analysis for enhanced accuracy. Expansion into emerging markets with tailored immunoassay solutions.

By 2035, the Immunoassay Market is expected to achieve substantial growth, reflecting evolving healthcare needs.

Market Segmentation

Immunoassay Market Type Outlook

  • Enzyme-Linked Immunosorbent Assay
  • Radioimmunoassay
  • Fluorescent Immunoassay
  • Chemiluminescent Immunoassay
  • Western Blot

Immunoassay Market End Use Outlook

  • Hospitals
  • Diagnostic Laboratories
  • Pharmaceutical Companies
  • Academic Research Institutions

Immunoassay Market Technology Outlook

  • Automated Immunoassay
  • Point of Care Immunoassay
  • Lateral Flow Assay

Immunoassay Market Application Outlook

  • Clinical Diagnostics
  • Drug Development
  • Environmental Testing
  • Food Safety Testing

Report Scope

MARKET SIZE 2024 25.25(USD Billion)
MARKET SIZE 2025 26.22(USD Billion)
MARKET SIZE 2035 38.3(USD Billion)
COMPOUND ANNUAL GROWTH RATE (CAGR) 3.86% (2025 - 2035)
REPORT COVERAGE Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR 2024
Market Forecast Period 2025 - 2035
Historical Data 2019 - 2024
Market Forecast Units USD Billion
Key Companies Profiled Abbott Laboratories (US), Roche Diagnostics (CH), Siemens Healthineers (DE), Thermo Fisher Scientific (US), Ortho Clinical Diagnostics (US), Bio-Rad Laboratories (US), Danaher Corporation (US), PerkinElmer (US), Fujirebio (JP)
Segments Covered Types, Technology, Applications, End Use, Regional
Key Market Opportunities Integration of advanced technologies enhances accuracy and efficiency in the Immunoassay Market.
Key Market Dynamics Technological advancements and regulatory changes drive innovation and competition in the Immunoassay Market.
Countries Covered North America, Europe, APAC, South America, MEA

FAQs

What is the current valuation of the Immunoassay Market as of 2024?

The Immunoassay Market was valued at 25.25 USD Billion in 2024.

What is the projected market size for the Immunoassay Market by 2035?

The market is projected to reach 38.3 USD Billion by 2035.

What is the expected CAGR for the Immunoassay Market during the forecast period 2025 - 2035?

The expected CAGR for the Immunoassay Market during 2025 - 2035 is 3.86%.

Which segment of the Immunoassay Market is expected to grow the most in terms of type?

The Enzyme-Linked Immunosorbent Assay segment is anticipated to grow from 10.5 USD Billion in 2024 to 16.0 USD Billion by 2035.

How does the Automated Immunoassay segment compare to other technologies in the market?

The Automated Immunoassay segment is projected to increase from 10.0 USD Billion in 2024 to 15.0 USD Billion by 2035, indicating strong growth.

What applications are driving growth in the Immunoassay Market?

Clinical Diagnostics is expected to expand from 10.5 USD Billion in 2024 to 16.0 USD Billion by 2035, leading the application segments.

Which end-use segment is likely to see the highest valuation by 2035?

The Hospitals segment is projected to grow from 8.5 USD Billion in 2024 to 12.5 USD Billion by 2035, suggesting robust demand.

Who are the key players in the Immunoassay Market?

Key players include Abbott Laboratories, Roche Diagnostics, Siemens Healthineers, and Thermo Fisher Scientific, among others.

What is the expected growth for the Drug Development application in the Immunoassay Market?

The Drug Development application is anticipated to grow from 6.0 USD Billion in 2024 to 9.0 USD Billion by 2035.

How does the growth of the Immunoassay Market reflect on environmental testing?

The Environmental Testing segment is projected to increase from 4.0 USD Billion in 2024 to 5.5 USD Billion by 2035, indicating a positive trend.

Author
Author
Author Profile
Vikita Thakur LinkedIn
Senior Research Analyst
She holds an experience of about 5+ years in market research and business consulting projects for sectors such as life sciences, medical devices, and healthcare IT. She possesses a robust background in data analysis, market estimation, competitive intelligence, pipeline analysis market trend identification, and consumer behavior insights. Her expertise lies in technical Sales support, client interaction and project management, designing and implementing market research studies, conducting competitive analysis, and synthesizing complex data into actionable recommendations that drive business growth.
Co-Author
Co-Author Profile
Rahul Gotadki LinkedIn
Research Manager
He holds an experience of about 9+ years in Market Research and Business Consulting, working under the spectrum of Life Sciences and Healthcare domains. Rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. His expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc.
Get In Touch
Leave a Comment

Research Approach

 

Secondary Research

The secondary research process involved comprehensive analysis of regulatory databases, peer-reviewed biomedical journals, clinical laboratory publications, and authoritative health organizations. Key sources included the US Food & Drug Administration (FDA) Center for Devices and Radiological Health (CDRH), Centers for Medicare & Medicaid Services (CMS) Clinical Laboratory Fee Schedule, European Medicines Agency (EMA) In Vitro Diagnostics Regulation (IVDR) database, World Health Organization (WHO) Essential Diagnostics List and Global Health Observatory, Centers for Disease Control and Prevention (CDC) Division of Laboratory Systems and National Center for Emerging and Zoonotic Infectious Diseases, National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID) and National Cancer Institute (NCI) clinical trial databases, Organisation for Economic Co-operation and Development (OECD) Health Statistics, World Bank Health, Nutrition and Population Statistics, American Association for Clinical Chemistry (AACC) Clinical Laboratory News, Clinical Laboratory Management Association (CLMA) industry reports, European Federation of Pharmaceutical Industries and Associations (EFPIA) data, Advanced Medical Technology Association (AdvaMed) industry forecasts, IQVIA Global In Vitro Diagnostics Insights, EvaluateMedTech market data, and national health ministry statistics from key diagnostics markets (China NMPA, Japan PMDA, India Central Drugs Standard Control Organization). These sources were utilized to collect procedure volumes, installed base data, regulatory approval timelines, clinical sensitivity/specificity studies, reimbursement code analysis, and competitive landscape intelligence for enzyme-linked immunosorbent assay (ELISA), chemiluminescent immunoassay (CLIA), radioimmunoassay (RIA), fluorescent immunoassay, and lateral flow technologies.

 

Primary Research

Qualitative and quantitative insights were obtained by interviewing supply-side and demand-side stakeholders during the primary research process. CEOs, VPs of Research & Development, global chiefs of In Vitro Diagnostics divisions, regulatory affairs specialists, and commercial directors from immunoassay platform manufacturers, reagent suppliers, and original equipment manufacturers (OEMs) comprised supply-side sources. Chief laboratory scientists, clinical pathologists, hospital laboratory directors, point-of-care coordinators, procurement heads from reference laboratories and hospital systems, pharmaceutical company heads of clinical operations, and academic research principal investigators comprised demand-side sources. Test volume projections were verified, product pipeline launch timelines were confirmed, and insights regarding automation adoption rates, reagent rental agreements, integrated system preferences, and regional pricing dynamics were obtained, all through primary research.

Primary Respondent Breakdown:

By Designation: C-level Primaries (32%), Director Level (30%), Others (38%)

By Region: North America (40%), Europe (25%), Asia-Pacific (28%), Rest of World (7%)

 

Market Size Estimation

Global market valuation was derived through revenue triangulation and test volume analysis across immunoassay platforms, reagents, and related software/services. The methodology included:

Identification of 55+ key manufacturers across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa specializing in automated analyzers, manual test kits, and point-of-care devices

Product mapping across chemiluminescent immunoassay, enzyme-linked immunosorbent assay, radioimmunoassay, fluorescent immunoassay, western blot, and lateral flow technologies

Analysis of reported annual revenues and estimated immunoassay-specific portfolio revenues for platform manufacturers and pure-play reagent suppliers

Coverage of manufacturers representing 75-80% of global market share in 2024, including comprehensive assessment of installed base units and average annual reagent consumption per analyzer

Extrapolation using bottom-up (test volume × average selling price by country/technology) and top-down (manufacturer revenue validation against serviceable obtainable market) approaches to derive segment-specific valuations for clinical diagnostics, pharmaceutical R&D, environmental testing, and food safety applications

Download Free Sample

Kindly complete the form below to receive a free sample of this Report

Customer Stories

Case Study Cover Image
Case Study
Aerospace & Defense
Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.